Interleaved fluid-attenuated inversion recovery (FLAIR) MRI and deuterium metabolic imaging (DMI) on human brain in vivo

Purpose To integrate deuterium metabolic imaging (DMI) with clinical MRI through an interleaved MRI and DMI acquisition workflow. Interleaved MRI-DMI was enabled with hardware and pulse sequence modifications, and the performance was demonstrated using fluid-attenuated inversion recovery (FLAIR) MRI as an example. Methods Interleaved FLAIR-DMI was developed by interleaving the H-2 excitation and acquisition time windows into the intrinsic delay periods presented in the FLAIR method. All H-2 MR signals were up-converted to the H-1 Larmor frequency using a custom-built hardware unit, which also achieved frequency and phase locking of the output signal in real-time. The interleaved measurements were compared with direct measurements both in phantom and in the human brain in vivo. Results The interleaved MRI-DMI acquisition strategy allowed simultaneous detection of FLAIR MRI and DMI in the same scan time as a FLAIR-only MRI acquisition. Both phantom and in vivo data showed that the MR image quality, DMI sensitivity as well as information content were preserved using interleaved MRI-DMI. Conclusion The interleaved MRI-DMI technology can be used to extend clinical MRI protocols with DMI, thereby offering a metabolic component to the MR imaging contrasts without a penalty on patient comfort or scan time.

Automated summary

In this study, the integration of deuterium metabolic imaging (DMI) with clinical MRI was achieved through an interleaved MRI and DMI acquisition technique. The interleaved acquisition strategy allowed simultaneous detection of FLAIR MRI and DMI without increasing the scan time, while preserving image quality, DMI sensitivity, and information content.